Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Terephthalamidine: past and future.

J S Fisherman1, E M Cline, J Plowman

  • 1Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Bethesda MD.

Investigational New Drugs
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Prevalence of undiagnosed atrial fibrillation in elderly individuals and potential cost-effectiveness of non-invasive ambulatory electrocardiographic screening: The ASSERT-III study.

Journal of electrocardiology·2019
Same author

Characterisation of white and black merino wools: a proteomics study.

Animal : an international journal of animal bioscience·2018
Same author

Animal board invited review: advances in proteomics for animal and food sciences.

Animal : an international journal of animal bioscience·2014
Same author

Stability of athlete blood passport parameters during air freight.

International journal of laboratory hematology·2013
Same journal

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Investigational new drugs·2026
Same journal

Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

Investigational new drugs·2026
Same journal

Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes.

Investigational new drugs·2026
Same journal

Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia.

Investigational new drugs·2026
Same journal

Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors.

Investigational new drugs·2026
Same journal

Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330.

Investigational new drugs·2026
See all related articles

Terephthalamidine, a compound from the 1960s, shows new promise for cancer treatment due to its unique structure and preclinical activity. Further studies will explore its clinical use and optimize dosing strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Repurposing

Background:

  • Terephthalamidine (NSC 57155) is a terephthalanilide derivative synthesized in the 1950s-1960s.
  • Initial clinical trials were halted due to severe neurotoxicity, despite observed responses in murine leukemias.
  • Recent preclinical screening identified renewed interest in terephthalamidine for antitumor activity.

Purpose of the Study:

  • To re-evaluate terephthalamidine for potential clinical investigation.
  • To investigate the drug's novel structure and preclinical activity spectrum.
  • To enable further clinical study through the development of a plasma assay.

Main Methods:

  • Preclinical synthesis and screening of terephthalanilides.
  • Historical clinical trial data review.

Related Experiment Videos

  • Development of a plasma assay for pharmacokinetic and pharmacodynamic analysis.

    • Main Results:

    • Terephthalamidine demonstrated preclinical antitumor activity.
    • Historical clinical trials showed some patient responses.
    • Severe neurotoxicity was a limiting factor in early trials.

    Conclusions:

    • Terephthalamidine is being reconsidered for clinical investigation due to its unique properties.
    • The availability of a plasma assay facilitates further pharmacokinetic and pharmacodynamic studies.
    • Optimized scheduling strategies may mitigate toxicity and improve therapeutic outcomes.